

Hong Kong-based genomics company Prenetics initiates new project to focus on accelerated ageing in space

12 February 2024 | News

Announces MoU for a strategic investment and 5-year research collaboration with Metavisionaries

Prenetics Global Limited, a leading genomics-driven health sciences company, has announced the signing of a Memorandum of Understanding (MoU), that paves the way for a strategic investment in Metavisionaries and a pioneering five-year research agreement with them and their partners Space Application Services through their Metaspace Venture.

The parties will also establish a Space Innovation Lab within the UAE Space Agency. The inaugural Prenetics research cube is scheduled to on-board the SpaceX to the ISS in Q4 of 2024.

As space exploration ignites a new era of discovery, the first endeavour by Prenetics will be with the Botnar Institute for Musculoskeletal Sciences at the University of Oxford, NDORMS (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences), led by Dr Ghada Alsaleh.

The joint project will be to research cellular solutions that promote rejuvenation and vitality to combat the phenomenon of accelerated ageing in space due to its zero-gravity environment. The potential of this research could lead to new advances in healthcare, enhancing cellular health and longevity for all ages on Earth.

Prenetics has also announced that Dr James L. Green, Chairman of Metavisionaries and former Chief Scientist of National Aeronautics and Space Administration (NASA), alongside Dr Tara Ruttley, Director of Sciences of Metavisionaries and former Associate Chief Scientist of NASA, will join the Prenetics Scientific Advisory Board. Concurrently, Danny Yeung, CEO of Prenetics will join the Board of Directors at Metavisionaries, fortifying its strategic vision.